Skip to main content
. 2016 Aug 1;33(15):1436–1449. doi: 10.1089/neu.2015.4186

FIG. 8.

FIG. 8.

FABP5 siRNA administration hinders locomotor recovery post-SCI. BBB locomotor scores were obtained every other day for 1 week post-SCI. Administration of 2 μg of FABP5 siRNA showed a transient impairment in locomotor recovery at 5 dpi when compared to animals receiving scrambled sequence oligos (n = 8–9 animals per group; two-way ANOVA; p < 0.01). Notably, concomitant administration of DHA and FABP5 siRNA abolished the beneficial effects of DHA to accelerate locomotor recovery at 7 dpi (n = 3–6 animals per group; two-way ANOVA; p < 0.001). *p < 0.05 when comparing FABP5 siRNA versus control at 5 dpi; **p < 0.001 when comparing DHA versus control at 7 dpi; ***p < 0.0001 when comparing DHA versus DHA + FABP5 siRNA at 7 dpi. ANOVA, analysis of variance; BBB, Basso-Beattie-Bresnahan locomotor scale; DHA, docosahexaenoic acid; dpi, days post-injury; FABP5, fatty acid binding protein 5; FITC, fluorescein isothiocyanate; ODN, oligodeoxynucleotide; SCI, spinal cord injury; siRNA, small interfering RNA.